Canada markets closed

LexaGene Holdings Inc. (LXXGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3735-0.0298 (-7.39%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.4033
Open0.3954
BidN/A x N/A
AskN/A x N/A
Day's Range0.3600 - 0.4000
52 Week Range0.2800 - 1.2200
Volume225,490
Avg. Volume201,884
Market Cap44.664M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-0.0920
Earnings DateJun. 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel

    Technology Accurately Identifies Pathogens and Predicts Antimicrobial Resistance In less than 30 years, drug resistant bacteria are predicted to kill 3 times more people on an annual basis than COVID-19 did in 2020MiQLab is a diagnostic tool used for detecting drug resistance at the point of care which will allow veterinarians to provide quality care for patients with suspected bacterial infectionsLexaGene’s MiQLab’s overall percent agreement in study: >99% for pathogen identification (106 sampl

  • CNW Group

    Small Cap Growth Conference: Live Executive Presentations on October 7th

    Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small Cap Growth Virtual Investor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, October 7th with the first live webcast at 9:00 AM ET.

  • GlobeNewswire

    LexaGene Expands Brand Awareness at Key Investor Conferences

    BEVERLY, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a commercial molecular diagnostics company selling a point-of-need highly multiplexed in-clinic PCR system with results in approximately two hours, today announced it will be featured at three investor relations conferences in early October. LexaGene management will also participate in one-on-one meetings at each conference. “Attending these conferences allows us t